Total amount: € 0,00
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1642
Rodolfo SACCO 1, Roberto EGGENHOFFNER 2, Luca GIACOMELLI 2
1 Department of Gastroenterology, Cisanello Hospital, Pisa, Italy; 2 Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa, Italy
Liver diseases markedly contribute to the global burden of mortality and morbidity. The pathogenesis of alcohol and non-alcohol induced liver diseases is complex and many factors have been described to contribute to the progressive loss of liver functions, including the over- generation of reactive oxygen species. The tripeptide glutathione (GSH) is the most important low molecular weight antioxidant synthesized in cells. In fact, GSH is a reducing molecule and it can react with oxygen species by neutralizing the unpaired electrons that make them highly reactive and dangerous. ROS over- production impairs the intracellular GSH homeostasis, leading to GSH deficiency, a pathophysiological hallmark in alcoholic and non-alcoholic liver diseases. On the basis of evidence obtained from experimental research and previous clinical studies, GSH administration appears a promising strategy to recover oxidative stress-induced liver damages in alcoholic and non-alcoholic liver diseases.